# Lamin B receptor upregulation in metastatic melanoma causes nuclear envelope fragility in confined migration during cancer invasion

**Authors:** Michelle A. Baird, Cayla E. Jewett, Daniela A. Malide, Lisa Kratz, Alexander X. Cartagena-Rivera, Robert S. Fischer, Clare M. Waterman

PMC · DOI: 10.1073/pnas.2513031123 · Proceedings of the National Academy of Sciences of the United States of America · 2026-02-18

## TL;DR

This study shows that increased LBR protein in melanoma makes the nucleus fragile, leading to DNA damage and cancer spread.

## Contribution

The study identifies LBR as a novel driver of nuclear envelope fragility in metastatic melanoma.

## Key findings

- LBR overexpression increases nuclear deformability and fragility in melanoma cells.
- LBR-induced nuclear ruptures correlate with increased metastasis and reduced patient survival.
- LBR's sterol reductase activity is essential for nuclear envelope instability in confined environments.

## Abstract

To metastasize, cancer cells migrate from the primary tumor through dense tissues to spread to distant organs. During this journey, as cells squeeze through thin passages in tissues, the membrane surrounding the cancer cell’s nucleus can burst, causing DNA damage and mutations, making it more malignant. We found that a specific protein, lamin B receptor (LBR), gets overproduced in aggressive melanoma. We found in isolated cancer cells that excess LBR causes cell nuclei to become more deformable and fragile, making them susceptible to rupture and that LBR-induced nuclear fragility happens in skin tumors in mice, increases cancer spreading, and correlates with decreased melanoma patient survival. This identifies LBR as a potential therapeutic target in the prevention of melanoma metastasis.

Cancer cells migrate through regions of tissue confinement during metastasis, causing nuclear envelope (NE) rupture, which generates heritable DNA damage and disease aggression. We sought to determine if NE rupture was intrinsic to malignant transformation and seek a mechanistic cause. We found that metastatic cells from multiple cancer subtypes have increased NE fragility in confinement compared to their benign counterparts. Meta-analysis of transcriptomic data from clinical samples of melanoma progression together with an siRNA-based live-cell confinement screen revealed that lamin B receptor (LBR) transcriptional upregulation correlates with melanoma progression and NE fragility. LBR is an inner nuclear membrane protein (INM) that scaffolds lamins and chromatin and has sterol reductase activity in the cholesterol biosynthesis pathway. Applying superresolution and atomic force microscopies to characterize the cellular and biophysical events leading to NE rupture revealed that upregulated LBR increased nuclear deformability and can generate local ruptures of the INM, promoting blebs in the nuclear membrane that burst to release nuclear contents into the cytoplasm. Structure–function analysis showed that LBR’s sterol reductase activity is required for its promotion of NE fragility in cells confined in vitro. Use of tumor organoids and an in vivo melanoma model revealed that upregulation of LBR was associated with increased NE fragility, metastatic invasion, and decreased patient survival. Thus, upregulation of LBR in melanoma promotes nuclear deformability, while LBR’s sterol reductase activity causes fragility and instability of the nuclear membrane, and these changes in the nucleus provide a possible mechanism for increased genetic heterogeneity in melanomas.

## Linked entities

- **Genes:** LBR (lamin B receptor) [NCBI Gene 3930]
- **Proteins:** LBR (lamin B receptor)
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** NUP214 (nucleoporin 214) [NCBI Gene 8021] {aka CAIN, CAN, IIAE9}, NUP153 (nucleoporin 153) [NCBI Gene 9972] {aka HNUP153, N153}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, LBR (lamin B receptor) [NCBI Gene 3930] {aka C14SR, DHCR14B, LMN2R, PHA, PHASK, TDRD18}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, LMNB2 (lamin B2) [NCBI Gene 84823] {aka EPM9, LAMB2, LMN2, MCPH27}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, SUN2 (Sad1 and UNC84 domain containing 2) [NCBI Gene 25777] {aka UNC84B, rab5IP}, CHMP2A (charged multivesicular body protein 2A) [NCBI Gene 27243] {aka BC-2, BC2, CHMP2, VPS2, VPS2A}, SYNE2 (spectrin repeat containing nuclear envelope protein 2) [NCBI Gene 23224] {aka EDMD5, KASH2, NUA, NUANCE, Nesp2, Nesprin-2}, LMNB1 (lamin B1) [NCBI Gene 4001] {aka ADLD, LMN, LMN2, LMNB, MCPH26}, EMD (emerin) [NCBI Gene 2010] {aka CMD3C, EDMD, LEMD5, STA}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, SYNE1 (spectrin repeat containing nuclear envelope protein 1) [NCBI Gene 23345] {aka 8B, AMC3, AMCM, ARCA1, C6orf98, CPG2}, CGAS (cyclic GMP-AMP synthase) [NCBI Gene 115004] {aka C6orf150, D4, MB21D1, h-cGAS}, TM7SF2 (transmembrane 7 superfamily member 2) [NCBI Gene 7108] {aka ANG1, C14SR, DHCR14A, NET47}, RANBP2 (RAN binding protein 2) [NCBI Gene 5903] {aka ADANE, ANE1, IIAE3, NUP358, TRP1, TRP2}, H2BC21 (H2B clustered histone 21) [NCBI Gene 8349] {aka GL105, H2B, H2B-GL105, H2B.1, H2BE, H2BFQ}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, NUP93 (nucleoporin 93) [NCBI Gene 9688] {aka NIC96}
- **Diseases:** NE (MESH:C564596), Melanoma (MESH:D008545), Cancer (MESH:D009369), skin cancer (MESH:D012878), NE fragility (MESH:D005600), melanoma metastasis (MESH:D009362), Greenberg's skeletal dysplasia (MESH:C535858), INM rupture (MESH:D005322), benign nevi (MESH:D009506), INM (MESH:D015433), 1 and 2 (MESH:C565121)
- **Chemicals:** F-MAS (MESH:C057525), streptomycin (MESH:D013307), PNAS (MESH:D020135), MbetaCD (MESH:C108732), lanosterol (MESH:D007810), cholesterol (MESH:D002784), GlutaMax (MESH:C054122), CaCl2 (MESH:D002122), penicillin (MESH:D010406), K+ (MESH:D011188), 1205Lu (-), cholesta-8,14-dien-3beta-ol (MESH:C002401), sterols (MESH:D013261), lipid (MESH:D008055), T-MAS (MESH:C071868), PDMS (MESH:C013830), DMSO (MESH:D004121), DAPI (MESH:C007293), simvastatin (MESH:D019821)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913]
- **Mutations:** V600, BRAFV600E, 583Q
- **Cell lines:** HEK293FT — Homo sapiens (Human), Transformed cell line (CVCL_6911), NCI-60 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_A592), MDA-MB-321 — Homo sapiens (Human), Finite cell line (CVCL_7279), 1205Lu — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_5239), MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), RWPE-1 — Homo sapiens (Human), Transformed cell line (CVCL_3791), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), NIH — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_5I45)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933115/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12933115/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933115/full.md

---
Source: https://tomesphere.com/paper/PMC12933115